Starpharma shares lift on trial results

Starpharma shares have risen after successful trials of its treatment for a condition that causes infertility and other problems for up to one in three women.

Shares in Starpharma have jumped on successful results for two advanced clinical trials of the biotech firm's treatment for bacterial vaginosis - a serious condition that can cause infertility and other serious problems.

Starpharma'sVivaGel showed effectiveness in trials to treat the condition - the most common cause of vaginal infection for women of child-bearing age and one that can lead to infertility, premature births and low birth weights as well as other complications.

Starpharma shares were 8.25 cents, or 10.9 per cent, higher at 84.25 cents at 1411 AEST.